Status:
ACTIVE_NOT_RECRUITING
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study
Lead Sponsor:
Tian Xie
Collaborating Sponsors:
LinkDoc Technology (Beijing) Co. Ltd.
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
Brief Summary
This is a nationwide, multicenter and retrospective cohort study. The purpose of this study is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cel...
Detailed Description
About 9.2%-45.8% of Chinese patients with Non-small cell lung cancer were positive for EGFR gene mutation. Gefitinib, Erlotinib, Icotinib, Afatinib showed efficacy superior to that of chemotherapy in ...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed advanced non-small cell lung cancer(stage IIIB\~IV).
- Patients with EGFR mutation.
- Received EGFR-TKIs at least once.
- Received Elemene Injectable Emulsion and/or Elemene Oral Emulsion at least once ( only for Elemene plus TKIs group).
- Completeness of important outcome measures and medical records related to the study.
Exclusion
- Accompanied by other active tumors.
- The researchers did not consider it appropriate to participate in this study for other reasons.
Key Trial Info
Start Date :
August 28 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 30 2026
Estimated Enrollment :
878 Patients enrolled
Trial Details
Trial ID
NCT04397432
Start Date
August 28 2020
End Date
March 30 2026
Last Update
December 27 2023
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China
2
Panjin Central Hospital
Panjin, Liaoning, China
3
Shenyang Tenth People's Hospital
Shenyang, Liaoning, China, 110000
4
The Second People's Hospital of Yangcheng County
Jincheng, Shanxi, China